BiotechTube

BNP7787 + Placebo

Phase 3Completed
0 watching 0 views this week📈 Rising
69
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Breast Neoplasms

Conditions

Breast Neoplasms, Breast Diseases, Metastases, Neoplasm

Trial Timeline

Sep 1, 2001 → Sep 1, 2014

NCT ID
NCT00039780

About BNP7787 + Placebo

BNP7787 + Placebo is a phase 3 stage product being developed by Lantern Pharma for Breast Neoplasms. The current trial status is completed. This product is registered under clinical trial identifier NCT00039780. Target conditions include Breast Neoplasms, Breast Diseases, Metastases, Neoplasm.

Hype Score Breakdown

Clinical
27
Activity
18
Company
2
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT00039780Phase 3Completed

Competing Products

20 competing products in Breast Neoplasms

See all competitors
ProductCompanyStageHype Score
LymphoseekNavidea BiopharmaceuticalsPhase 3
69
LymphoseekNavidea BiopharmaceuticalsPhase 3
69
ALT-P7 (HM2-MMAE)AlteogenPhase 1
33
Biomarkers blood, urine and microbiota samplesEli LillyPre-clinical
23
gemcitabine + paclitaxel + bevacizumabEli LillyPhase 2
52
Gemcitabine + Adriamycine + PaclitaxelEli LillyPhase 2
52
Abemaciclib + FulvestrantEli LillyPhase 2
52
VS-6766 + Abemaciclib + FulvestrantEli LillyPhase 1/2
41
gemcitabine + vinorelbineEli LillyPhase 2
52
Abemaciclib + Fulvestrant + PlaceboEli LillyPhase 3
77
Azenosertib + Carboplatin + PembrolizumabZentalis PharmaceuticalsPhase 1/2
33
AbemaciclibEli LillyPre-clinical
23
pemetrexed + cyclophosphamide + doxorubicin + docetaxelEli LillyPhase 2
52
arzoxifeneEli LillyApproved
85
BBI-355 + Erlotinib + Futibatinib + BBI-825Boundless BioPhase 1
25
BBI-940 + FulvestrantBoundless BioPhase 1
25
LY4064809 + Placebo + Ribociclib + Palbociclib + Abemaciclib + Anastrozole + Letrozole + Exemestane + FulvestrantEli LillyPhase 3
77
pemetrexed + gemcitabineEli LillyPhase 2
52
Experimental Arm A: Pemetrexed + Experimental Arm A: Sorafenib + Experimental Arm B: Pemetrexed + Experimental Arm B: SorafenibEli LillyPhase 2
52
pemetrexedEli LillyPhase 2
52

Other Products from Lantern Pharma

Tavocept(BNP7787) in combination with cisplatin and either docetaxel or paclitaxel + Placebo in combination with cisplatin and docetaxel or paclitaxelPhase 3
69
IrofulvenPhase 2
44
LP-300 + Pemetrexed + CarboplatinPhase 2
44
LP-184 + Spironolactone + OlaparibPhase 1/2
33
STAR-001 (LP-184) will be administered via IV infusion over 30 (± 5) minutes on Day 1 and Day 8 of each 21-day cycle. + Spironolactone (drug)Phase 1/2
33